EUCTR2007-002734-11-PL进行中（未招募）1 期
A 6-week, phase III, double-blind, randomized, multi-centre, parallel-group study evaluating the efficacy and safety of 2 actuations Symbicort® (budesonide/formoterol) pMDI 40/2.25 µg twice daily compared with 1 inhalation Symbicort Turbuhaler® 80/4.5 µg twice daily and 1 inhalation Pulmicort® (budesonide) Turbuhaler® 100 µg twice daily in adult and adolescent asthmatics
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 600
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •For inclusion in the study, patients must fulfill all of the following criteria at Visit 2:
- •1. Signed informed consent from the patient. For the under-aged patients, signed informed consent is required from both the patient and the patient's parent/legal guardian.
- •2. Out-patients of either sex, 12 years and above.
- •3. Asthma according to the American Thoracic Society (ATS) definition, clinically diagnosed at least 6 months prior to Visit 2.
- •4. Pre-bronchodilator FEV1 = ?50% and = ?90% of predicted normal.
- •5. Patients with reversible airway obstruction (from a reversibility test performed at Visit 2), defined as an increase in FEV1 of = 12% relative to baseline (for all patients), and for patients =18 years =200 mL after inhalation of in total 1 mg Bricanyl Turbuhaler..
- •6. Daily use of inhaled GCS (any brand) for >3 months prior to Visit 2.
- •7. During 30 days prior to Visit 2, the dose of inhaled GCS should have been constant and within the range of 200-500 µg/day (any brand).
- •8. Ability to use pMDI, Turbuhaler, and peak flow meter correctly.
- •9. Able to read and write and use the electronic devices.
- •For randomization into the study, patients must fulfill all of the following criteria at Visit 3:
- •1. Run-in diary data for mPEF recorded on at least 7 (any 7) of the last 10 days of the run-in period (including the day of Visit 3).
- •2. Total asthma symptom score (night-time plus daytime) of >1 on at least 4 (any of the last 7 days of the run-in period (not including the recording in the morning of Visit 3.
- •3. No change in asthma treatment during the run-in period.
- •4. Continued eligibility for the study in accordance with the exclusion criteria.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Use of oral, rectal or parenteral GCS within 30 days prior to Visit 2.
- •2. Respiratory infection affecting the asthma, as judged by the investigator, within 30 days prior to Visit 2.
- •3. Any significant disease or disorder which, in the opinion of the investigator, may either put the patient at risk because of participation in the study, or may influence the results of the study or the patient's ability to participate in the study.
- •4. Any clinically relevant abnormal findings in physical examination, clinical chemistry, haematology, urinalysis, vital signs at baseline visit, which, in the opinion of the investigator, may put the patient at risk because of his/her participation in the study.
- •5. Pregnancy, breast-feeding or planned pregnancy during the study. Women and where applicable, girls of child-bearing potential without acceptable contraceptive measures as judged by the investigator.
- •6. Known or suspected hypersensitivity to budesonide, formoterol, inhaled lactose, PVP K25, PEG 1000, HFA-227.
- •7. Present use of any ß-blocker (including eye-drops).
- •8. History of = 10 pack-years of smoking (i.e. equivalent of smoking 20 cigarettes per day for 10 years).
- •9. Planned donation of blood during the study.
- •10. Planned hospitalization during the study.
- •11. Suspected poor capability, as judged by the investigator, to follow instructions of the study, e.g., because of a history of alcohol or drug abuse.
- •12. Participation in another clinical study of any investigational drug within 30 days prior to or during the course of the study.
- •13. Previous allocation of randomization code in this study.
- •14. Involvement in the planning and conduct of the study (applies to both AstraZeneca staff or staff at the study site)
研究者
相似试验
进行中（未招募）
不适用
A 6-week, phase III, double-blind, randomized, multi-centre, parallel-group study evaluating the efficacy and safety of 2 actuations Symbicort® (budesonide/formoterol) pMDI 40/2.25 µg twice daily compared with 1 inhalation Symbicort Turbuhaler® 80/4.5 µg twice daily and 1 inhalation Pulmicort® (budesonide) Turbuhaler® 100 µg twice daily in adult and adolescent asthmatics - ESTHERMedDRA version: 9.1Level: LLTClassification code 10003553Term: AsthmaasthmaEUCTR2007-002734-11-HUAstraZeneca AB600
进行中（未招募）
1 期
A 6-week, phase III, double-blind, randomized, multi-centre, parallel-group study evaluating the efficacy and safety of 2 actuations Symbicort® (budesonide/formoterol) pMDI 40/2.25 µg twice daily compared with 1 inhalation Symbicort Turbuhaler® 80/4.5 µg twice daily and 1 inhalation Pulmicort® (budesonide) Turbuhaler® 100 µg twice daily in adult and adolescent asthmaticsMedDRA version: 9.1Level: LLTClassification code 10003553Term: AsthmaasthmaEUCTR2007-002734-11-CZAstraZeneca AB600
进行中（未招募）
1 期
A Phase 3, randomized, 6-month, double blind trial in subjects with Bipolar I Disorder to evaluate the continued safety and maintenance of effect of Ziprasidone plus a mood stabilizer (vs placebo plus a mood stabilizer) following a minimum of 4 months of response to open-label treatment with both agents.Bipolar I DisorderMedDRA version: 8.0Level: LLTClassification code 10004939EUCTR2005-004167-27-ESPfizer, S.A.512
进行中（未招募）
不适用
A Phase 3, randomized, 6-month, double blind trial in subjects with Bipolar I Disorder to evaluate the continued safety and maintenance of effect of Ziprasidone plus a mood stabilizer (vs placebo plus a mood stabilizer) following a minimum of 2 months of response to open-label treatment with both agents. - NAMedDRA version: 8.0Level: LLTClassification code 10004939Bipolar I DisorderEUCTR2005-004167-27-DEPfizer Pharma GmbH512
进行中（未招募）
不适用
A Phase 3, randomized, 6-month, double blind trial in subjects with Bipolar I Disorder to evaluate the continued safety and maintenance of effect of Ziprasidone plus a mood stabilizer (vs placebo plus a mood stabilizer) following a minimum of 2 months of response to open-label treatment with both agents.(Clinical pharmacogenomics supplement amended) - NAMedDRA version: 8.0Level: LLTClassification code 10004939Bipolar I DisorderEUCTR2005-004167-27-SEPfizer AB512